LEXICON PHARMACEUTICALS, INC. (LXRX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Annual

0 150M 300M 450M FY16: 79.3M FY17: 91.7M FY18: 63.2M FY19: 322.1M FY20: 24M FY21: 298K FY22: 139K FY23: 1.2M FY24: 31.1M FY25: 49.8M FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Gross Profit Annual

0 150M 300M 450M FY16: 79.3M FY17: 89.8M FY18: 60.7M FY19: 318.8M FY20: 22.1M FY21: 298K FY22: 139K FY23: 1.1M FY24: 30.5M FY25: 49.5M FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Annual

-210M -140M -70M 0 70M 140M 210M FY16: -127.2M FY17: -130.6M FY18: -103.3M FY19: 141.4M FY20: -47.8M FY21: -87.1M FY22: -100.8M FY23: -171.8M FY24: -197.1M FY25: -48.9M FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Net Income Annual

-210M -140M -70M 0 70M 140M 210M FY16: -131.4M FY17: -123M FY18: -120.5M FY19: 130.1M FY20: -58.6M FY21: -87.8M FY22: -101.9M FY23: -177.1M FY24: -200.4M FY25: -50.3M FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Cost of Revenue Annual

0 1.5M 3M 4.5M FY16: 0 FY17: 1.9M FY18: 2.5M FY19: 3.2M FY20: 1.9M FY21: 0 FY22: 0 FY23: 85K FY24: 616K FY25: 274K FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Operating Cash Flow Annual

-210M -140M -70M 0 70M 140M 210M FY16: -175.6M FY17: -185.4M FY18: -148.6M FY19: 113.8M FY20: -143M FY21: -87M FY22: -88.9M FY23: -161.9M FY24: -178.8M FY25: -67.9M FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Free Cash Flow Annual

-210M -140M -70M 0 70M 140M 210M FY16: -175.9M FY17: -185.6M FY18: -148.7M FY19: 113.7M FY20: -143.1M FY21: -88.2M FY22: -90.2M FY23: -162.4M FY24: -179.8M FY25: -67.9M FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 150M 300M 450M FY17: 105.2M FY18: 105.8M FY19: 116.7M FY20: 110.8M FY21: 145.7M FY22: 165.7M FY23: 221.1M FY24: 320M FY25: 363.1M FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-1.50 -1.00 -0.50 0.00 0.50 1.00 1.50 Q3 '16: -0.30 Q4 '16: -1.37 Q1 '17: -1.36 Q2 '17: -1.32 Q3 '17: -1.26 Q4 '17: -1.20 Q1 '18: -1.27 Q2 '18: -1.27 Q3 '18: -1.24 Q4 '18: -1.15 Q1 '19: -0.96 Q2 '19: -0.85 Q3 '19: 1.36 Q4 '19: 1.04 Q1 '20: 0.62 Q2 '20: 0.19 Q3 '20: -1.05 Q4 '20: -0.60 Q1 '21: -0.12 Q2 '21: 0.40 Q3 '21: -0.47 Q4 '21: -0.61 Q1 '22: -0.62 Q2 '22: -0.65 Q3 '22: -0.62 Q4 '22: -0.62 Q1 '23: -0.63 Q2 '23: -0.69 Q3 '23: -0.77 Q4 '23: -0.80 Q1 '24: -0.83 Q2 '24: -0.78 Q3 '24: -0.75 Q4 '24: -0.64 Q1 '25: -0.51 Q2 '25: -0.33 Q3 '25: -0.19 Q4 '25: -0.14 Q1 '26: -0.07 Q2 '26: -0.15 Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.